Liver transplantation for hepatic epithelioid hemangioendothelioma: The Canadian multicentre experience

Carmine G Nudo MD1, Eric M Yoshida MD2, Vincent G Bain MD3, Denis Marleau MD4, Phil Wong MD5, Paul J Marotta MD6, Eberhard Renner MD7, Kymberly D Watt MD8, Marc Deschênes MD1

INTRODUCTION: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare entity. At the present time, there is no standardized effective therapy. Liver transplantation (LT) has emerged as a treatment for this rare tumour.

OBJECTIVE: To evaluate the outcome of liver transplantation for HEHE at eight centres across Canada.

METHODS: The charts of patients who were transplanted for HEHE at eight centres across Canada were reviewed.

RESULTS: A total of 11 individuals (eight women and three men) received a LT for HEHE. All LTs were performed between 1991 and 2005. The mean (± SD) age at LT was 38.7±13 years. One patient had one large liver lesion (17 cm × 14 cm × 13 cm), one had three lesions, one had four lesions and eight had extensive (five or more) liver lesions. One patient had spleen involvement and two had involved lymph nodes at the time of transplantation. The mean duration of follow-up was 78±63 months (median 81 months). Four patients (36.4%) developed recurrence of HEHE with a mean time to recurrence of 25±25 months (median 15.6 months) following LT. The calculated survival rate following LT for HEHE was 82% at five years.

CONCLUSIONS: The results of LT for HEHE are encouraging, with a recurrence rate of 36.4% and a five-year survival rate of 82%. Further studies are needed to help identify patients who would benefit most from LT for this rare tumour.

Key Words: Hepatic epithelioid hemangioendothelioma; Liver; Transplantation

Heaptic epithelioid hemangioendothelioma (HEHE) is a rare indication for liver transplantation (LT). Epithelioid hemangioendothelioma is a rare vascular tumour that was first described by Weiss and Enzinger in 1982 (1). It has been described in many different organs such as the spleen, bone, brain, meninges, breast, heart, head and neck, soft tissue, stomach and lymph nodes (1-6). In 1984, Ishak et al (7) reported a series of 32 patients with HEHE.

Primary malignant HEHEs are rare, with an incidence of one per million population (8). HEHE has a 3:2 preponderance for females (9) and occurs most often in adults, with a peak incidence between 30 and 40 years of age (10). There are no clear risk factors for the development of HEHE, although liver trauma, hormones, vinyl chloride, asbestos, Thorotrast contrast, alcohol and viral hepatitis may be implicated (9,10).
Most patients with HEHE are asymptomatic at the time of diagnosis. If symptoms are present, they are nonspecific, and may include weight loss and right upper quadrant pain. Some patients may also present with jaundice and liver failure (7). Hepatic failure is likely due to replacement of liver parenchyma by the tumour.

Physical findings may include hepatomegaly, a palpable mass or jaundice (9). Many patients will have mild elevations in serum bilirubin, alkaline phosphatase and aspartate aminotransferase levels. Alpha-fetoprotein and cancer antigen 19-9 levels are normal. Carcinoembryonic antigen may be elevated (10).

Lesions are often hypoechoic on ultrasound (11,12), but may have a mixed echotexture or be hyperechoic (13). Typical computed tomography findings include hypoattenuated tumour in both lobes that coalesce to form larger confluent regions in a peripheral or subcapsular distribution. A halo or target pattern of enhancement can be seen in larger lesions (11,12). The extent of lesions may be better appreciated with unenhanced computed tomography (12). Calcifications may be present in 20% of patients (10). On magnetic resonance imaging, lesions are hypointense relative to normal liver on unenhanced T1-weighted images and heterogeneously increased signal intensity on T2-weighted images (4,8,9,14,15).

Histological findings are characterized by epithelioid or histiocytoid morphology (14). Intravascular spread into terminal hepatic venules and portal vein branches is common (9). Vascular characteristics of the tumour can be confirmed with staining for factor VIII-related antigen and other endothelial cell markers (CD31, CD34) (10).

The natural history of HEHE is unpredictable, with a clinical course between benign hemangioma and angiosarcoma (10,14,16). Metastases have been reported in 27% of patients and most commonly occur in the lungs (3). The mortality rate is reported at more than 65%. HEHE can be treated with liver resection, orthotopic LT, chemotherapy, radiotherapy or immunotherapy (9). Because HEHE is rare, the effectiveness of these therapies has not been formally assessed.

The aim of the present study was to evaluate the Canadian experience of LT for HEHE.

METHODS

All eight centres performing LT or involved in the care of LT patients participated in the study. The charts of patients transplanted for HEHE at eight centres across Canada were reviewed. Data collected included patient age, sex, indication for LT, duration of follow-up, tumour recurrence, therapy for the tumour before transplantation and for recurrences, and patient survival.

Statistical analysis

The data collected were used to calculate the rate of and time to recurrence and death. Kaplan-Meier survival curves for disease-free survival and patient survival for patients transplanted for HEHE were also calculated.

RESULTS

A total of 11 individuals underwent LT for HEHE. All LTs were performed between 1991 and 2005. All liver grafts were from deceased donors. The characteristics of patients transplanted for HEHE are shown in Table 1. Eleven patients received a LT for HEHE, of whom eight were female and three were male. The mean (± SD) age at transplantation was 38.7±13 years. One patient underwent an early repeat LT for hepatic artery thrombosis and died soon after the second LT. One patient had one large liver lesion, one had three lesions, one had four lesions and nine had extensive (five or more) liver lesions. One patient had spleen involvement and two had positive lymph nodes at the time of transplantation.
The mean duration of follow-up after transplantation was 78±63 months (median 81 months). Four patients received adjuvant therapy for HEHE before LT (interferon therapy [n=1], splenectomy [n=1], adriamycin therapy [n=1] and surgical resection [n=1]).

Four patients (36.4%) developed recurrence of HEHE following LT, with a mean time to recurrence of 25±25 months (median 15.6 months). Two patients with recurrence in the liver were treated with tumour resection; one of these patients underwent a repeat LT (Table 1). One patient with bone recurrence was treated with radiotherapy for pain. A fourth patient with liver and spleen recurrence was treated with pegylated interferon.

The one-year disease-free survival rate was 80%, and the three- and five-year disease-free survival rates were 69% (Figure 1). Beyond five years, the disease-free survival rate was 55%.

Three patients (27%) died during the follow-up period (Table 1). One patient died from tumour-related complications, one secondary to hepatic artery thrombosis and the third of unknown cause. The calculated survival rate following LT for HEHE was 82% at five years (Figure 2). Beyond five years, the survival rate was 70%.

**DISCUSSION**

Because HEHE is rare, no therapy has been clearly established. LT has emerged as one possible therapy for these conditions. The aim of our study was to evaluate the Canadian experience of LT for HEHE.

In our study, the disease-free survival rate was 80% at one year, and 69% at three and five years for HEHE following LT (Figure 1). The overall survival rate was 82% at one, three and five years (Figure 2). Our results are comparable with previously published data. In a single-centre report (17), 16 patients were transplanted for HEHE with a median follow-up period of 4.5 years (54 months). The disease-free survival rates at one, three and five years were 81.3%, 68.8% and 60.2%, respectively. The survival rates were 100%, 87.5% and 73.3%, respectively. Another published series (18) of 21 patients had a 33% incidence of tumour recurrences and a two-year survival rate of 82%. In a review (9) of 434 published cases of HEHE, 33% incidence of tumour recurrences and a two-year survival rate of 82%.

The results of the study indicated that pretransplant medical status correlated with patient survival. Of the 38 patients who died, 12 (32%) had recurrent HEHE.

Fifty-nine patients transplanted for HEHE were reported to the European Liver Transplant Registry (19). Fourteen patients (23.7%) developed disease recurrence at a median time of 49 months and nine (15.3%) died of recurrent disease. One-, five- and 10-year post-LT survival rates were 93%, 83% and 72%, respectively. Disease-free survival rates were 90%, 82% and 64%, respectively. Disease-free survival was not significantly influenced by pre-LT treatment, lymph node status, extrahepatic disease or vascular invasion.

The outcomes of LT for HEHE in the United States from the United Network for Organ Sharing database were recently published (20). One hundred nine patients with HEHE underwent 128 transplantations between 1987 and 2005. Patient survival rates at one and five years were 80% and 64%, respectively. Allograft survival rates were 70% and 55%, respectively. The results of the study indicated that pretransplant medical status correlated with patient survival. Of the 38 patients who died, 12 (32%) had recurrent HEHE.

Most patients with HEHE have large, multifocal tumours at the time of diagnosis. Approximately 20% die within two years after the diagnosis and only 20% survive more than five years after diagnosis (14). The benefit of liver resection for HEHE is restricted to patients with limited involvement of the liver. For patients with unresectable multifocal tumours, LT remains a reasonable treatment option, even in patients with extrahepatic liver disease (21,22). The five-year survival rate of patients who underwent LT for HEHE in our study and that of patients in previously published papers is comparable with the survival rate of patients transplanted for cirrhosis (23).
HEHE should be considered in the differential diagnosis of all patients with a hepatic mass. Liver resection should be considered for patients with limited disease. LT should be considered for patients with extensive disease. The results of LT for HEHE are encouraging, with a recurrence rate of 36.4% and a five-year survival rate of 82%, which is comparable with LT for cirrhosis. Further studies are needed to help identify patients who would benefit most from liver transplantation.

REFERENCES
